In a randomized Phase III study of the drug inotuzumab ozogamicin, a statistically significant percentage of patients with acute lymphoblastic leukemia (ALL) whose disease had relapsed following standard therapies, qualified for stem cell transplants.
This summer, many preschoolers across Texas are safely enjoying their vacation time outdoors thanks to Ray and the Sunbeatables™, a sun-safety program developed by researchers at MD Anderson Cancer Center.
Proton therapy hasn’t been documented in clinical trials for patients with non–small cell lung cancer — until now. Two ongoing trials may change the standard of care for the most common type of lung cancer.
Researchers with MD Anderson’s Colorectal Cancer Moon Shot are sharpening the focus of a genetic tool designed to classify colorectal cancer into one of four categories — a vital step toward improving treatment.
Using an innovative approach to identify a cancer’s genetic vulnerabilities by more quickly analyzing human tumors transplanted into mice, researchers identified a new potential target for pancreatic cancer treatment.
Traditionally, patients in the U.S. have received smaller doses of radiation over a longer period of time. But new research has shown higher doses over less time yield equivalent results with the added bonus of a more convenient treatment schedule.